Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants
Open Access
- 21 September 2018
- journal article
- research article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 15 (2), 327-338
- https://doi.org/10.1080/21645515.2018.1526586
Abstract
This phase III, open-label, randomized study (NCT01978093) evaluated the immunogenicity and safety of co-administered Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y–tetanus toxoid conjugate vaccine (Hib-MenCY-TT) with human rotavirus vaccine (HRV), hepatitis A vaccine (HAV) and 13-valent pneumococcal conjugate vaccine (PCV13). We randomized 600 infants (1:1) to receive 4 doses of Hib-MenCY-TT at 2, 4, 6 and 12–15 months of age or 3 doses of Hib vaccine conjugated to N. meningitidis outer membrane protein complex (Hib-OMP) at 2, 4 and 12–15 months of age. All infants received HRV at 2 and 4 months of age, PCV13 at 2, 4, 6 and 12–15 months of age, HAV at 12–15 and 18–21 months of age, and diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months of age. We measured immune responses against HRV, HAV and Hib with enzyme-linked immunosorbent assays, and against MenC/MenY with serum bactericidal assays using human complement. The 4-dose vaccination series with Hib-MenCY-TT induced a robust immune response against Hib, which was non-inferior to that induced by a 3-dose vaccination series with Hib-OMP, and against MenC and MenY. Hib-MenCY-TT did not interfere with immune responses to concomitantly administered HRV, PCV13 and HAV. We did not identify any safety concern. In conclusion, we showed that 4-dose vaccination series with Hib-MenCY-TT during infancy did not interfere with immune responses of co-administered HRV, PCV13 and HAV, induced robust immune responses against Hib, MenC and MenY, and had a clinically acceptable safety profile.Keywords
Funding Information
- GlaxoSmithKline Biologicals S.A
This publication has 24 references indexed in Scilit:
- Epidemiology of community-acquired bacterial meningitisCurrent Opinion in Infectious Diseases, 2018
- Current Epidemiology and Trends in Meningococcal Disease—United States, 1996–2015Clinical Infectious Diseases, 2017
- Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational studyThe Lancet Infectious Diseases, 2014
- MenHibrixAnnals of Pharmacotherapy, 2013
- Bacterial Meningitis Post–PCV7Pediatric Emergency Care, 2013
- Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlersHuman Vaccines & Immunotherapeutics, 2012
- Immunogenicity and Safety of H influenzae Type b–N meningitidis C/Y Conjugate Vaccine in InfantsPEDIATRICS, 2011
- Bacterial Meningitis in the United States, 1998–2007The New England Journal of Medicine, 2011
- Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.Human Vaccines, 2011
- Randomized Trial to Assess Immunogenicity and Safety of Haemophilus influenzae Type b and Neisseria meningitidis Serogroups C and Y–Tetanus Toxoid Conjugate Vaccine in InfantsThe Pediatric Infectious Disease Journal, 2010